$16.17
+0.87 (+5.69%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where AUPH is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 1 observational · 9 with posted results
Held by 14 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, D. E. Shaw & Co., Inc., AQR CAPITAL MANAGEMENT LLC, +9 more) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · insider 90d: 5 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study of Aritinercept in Patients With Generalized Myasthenia GravisNCT07596901To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1/2 | Recruiting | Drug: Aritinercept · Other: Placebo | Myasthenia Gravis, Generalized | 81 | 2029-03-02 | in 925 d | 2026-08-03 |
| PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus NephritisNCT07611214To assess the efficacy of LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response: Proportion of patients with complete renal response at 24 weeksOpen-label · Treatment | Phase 4 | Recruiting | Drug: LUPKYNIS, mycophenolic acid analog (MPAA), corticosteroid · Biological: belimumab, obinutuzumab or anifrolumab | Lupus Nephritis | 150 | 2029-03-02 | in 925 d | 2026-08-03 |
| Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus NephritisNCT05962788Incidence of Treatment Emergent Adverse Events (TEAE)Open-label · Treatment | Phase 3 | Terminatedsponsor's stated reason: DSMB recommendation | Drug: voclosporin | Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | 4 | 2025-07-04actual | — | 2026-02-10 |
| Voclosporin in Adolescent and Pediatric Subjects With Lupus NephritisNCT05288855Proportion of subjects with renal responseRandomized · Quadruple-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: DSMB recommendation | Drug: Voclosporin, Placebo Oral Capsule | Adolescent Lupus Nephritis, Pediatric Lupus Nephritis | 9 | 2025-07-03actual | — | 2026-02-10 |
| A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the USNCT05337124observationalLUPKYNIS utilization patterns | — | Completed | Drug: LUPKYNIS | Lupus Nephritis | 229 | 2025-01-31actual | — | 2025-06-24 |
| Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of SimvastatinNCT05306379Pharmacokinetics of simvastatin and simvastatin acid (Cmax)Open-label · Other | Phase 1 | Completed | Drug: Simvastatin, Voclosporin | Drug-drug Interaction | 24 | 2022-04-05actual | — | 2022-04-20 |
| Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With VoclosporinNCT03597464results2022-12-14Adverse Events (AE) Profile and Routine Biochemical and Hematological Assessments.Randomized · Quadruple-masked · TreatmentStudy Protocol: Protocol v1.0 ↗ · Study Protocol: Protocol v2.0 ↗ · Study Protocol: Protocol v3.0 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Voclosporin, Placebo Oral Capsule | Lupus Nephritis | 216 | 2021-10-07actual | — | 2022-12-14 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye SyndromeNCT04147650results2021-12-10Number of Subjects With a ≥10 mm Increase From Baseline in Schirmer Tear Test (STT)Randomized · Double-masked · TreatmentStudy Protocol: Version 1.0 ↗ · Study Protocol: Version 2.0 ↗ · Study Protocol: Version 3.0 ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution | Dry Eye Syndrome, Keratoconjunctivitis Sicca | 508 | 2020-09-17actual | — | 2021-12-10 |
| Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental GlomerulosclerosisNCT03598036results2021-09-16Proportion of Subjects With Remission of ProteinuriaOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan: Protocol v1.0 ↗ · Study Protocol and Statistical Analysis Plan: Protocol v2.0 (Amendment 1) ↗ · Study Protocol and Statistical Analysis Plan: Protocol v3.0 (Amendment 2) ↗ · Study Protocol and Statistical Analysis Plan: Protocol v4.0 (Amendment 3) ↗ | Phase 2 | Terminatedsponsor's stated reason: Low recruitment rate | Drug: Voclosporin | Focal Segmental Glomerulosclerosis | 5 | 2020-05-19actual | — | 2021-09-16 |
| Aurinia Renal Response in Active Lupus With VoclosporinNCT03021499results2021-06-16Number of Participants With Adjudicated Renal Response at Week 52Randomized · Quadruple-masked · TreatmentStudy Protocol: Protocol V1.0 01Dec2016 ↗ · Study Protocol: Protocol V2.0 04May2017 ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Voclosporin, Placebo Oral Capsule | Lupus Nephritis | 358 | 2019-09-24actual | — | 2023-03-27 |
| Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye DiseaseNCT03597139results2021-07-08Change From Baseline in Drop Discomfort Post Dose Instillation on Day 1Randomized · Single-masked · TreatmentStudy Protocol: aur-vos-2017-01-protocol-v1_Redacted ↗ · Study Protocol: aur-vos-2017-01-protocol-v2_Redacted ↗ · Study Protocol: aur-vos-2017-01-protocol-v3_Redacted ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Voclosporin Ophthalmic Solution, Restasis® | Dry Eye | 100 | 2018-11-09actual | — | 2021-07-08 |
| Aurinia Early Urinary Protein Reduction Predicts ResponseNCT02949973results2021-03-19Number of Participants With Reduction or Normalization of Urine Protein/Creatinine Ratio (UPCR)Open-label · Treatment | Phase 2 | Completed | Drug: voclosporin | Lupus Nephritis | 10 | Dec 2016actual | — | 2021-03-19 |
| Voclosporin in Healthy Japanese VolunteersNCT02949999Incidence of treatment emergent adverse eventsRandomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Voclosporin | Volunteers | 40 | Dec 2016actual | — | 2018-01-17 |
| AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)NCT02141672results2021-05-18Number of Subjects Achieving Complete Renal Remission at 24 WeeksRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Voclosporin High Dose, Voclosporin Low Dose, Placebo | Lupus Nephritis | 265 | Jul 2016actual | — | 2021-05-18 |
| Safety and Efficacy Study of Voclosporin and Tacrolimus in TransplantationNCT01586845The primary endpoint to assess non-inferiority will be efficacy failure at the end of Month 12 after randomization.Randomized · Single-masked · Prevention | Phase 3 | Withdrawn | Drug: voclosporin, tacrolimus | Renal Transplantation | 0 | Dec 2015 | — | 2014-01-20 |
| Study of ISA247 (Voclosporin) in De Novo Renal TransplantationNCT00270634results2013-02-12Biopsy Proven Acute Rejection (BPAR)Randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Voclosporin, tacrolimus | Kidney Diseases | 334 | Jul 2009actual | — | 2013-02-12 |
| Randomized, Placebo and Ciclosporin Controlled Study of ISA247 in Plaque Psoriasis PatientsNCT00408187Superiority in the proportion of subjects achieving a score of "clear" or "almost clear" in the Static Physician's Global Assessment (SPGA) scoreRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: voclosporin, Ciclosporin, Placebo | Psoriasis | 642 | Dec 2008actual | — | 2009-07-30 |
| A 36-Week Extension to Protocol ISA04-03NCT00258713To investigate long-term safety and tolerability of voclosporinRandomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: voclosporin | Psoriasis | 309 | Jul 2006actual | — | 2008-09-29 |
| Randomized Placebo-controlled Study of ISA247 in Plaque PsoriasisNCT00244842results2023-03-27Proportion of Subjects Achieving a PASI-75 at 12 Weeks at Each of the 3 Dose Levels of Voclosporin.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: voclosporin, Placebo | Psoriasis | 451 | Oct 2005actual | — | 2023-03-27 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19